Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was started at 5 mg/kg/ day when PCR reached 300 copies per ml or when antigenemia reached three positive cells per two slides. A total of 88 patients were randomized into the antigenemia group (n ¼ 45) or the PCR group (n ¼ 43). A significantly higher number of patients reached the threshold in the antigenemia group than in the PCR group (73.3 vs 44.2%, P ¼ 0.0089). However, only three patients (one in the antigenemia group and two in the PCR group) developed early CMV disease. These patients exclusively had colitis and were successfully treated with GCV or foscarnet. The median number of antigenemia-positive cells at the start of GCV was 47 in the PCR group. These findings suggest that antigenemia assay with the current cutoff was too sensitive and led to unnecessary use of GCV. However, the appropriateness of the threshold may be different by the methodology used, and therefore, it is difficult to generalize.
Introduction
Cytomegalovirus infection is a frequent complication after allogeneic hematopoietic SCT. Universal prophylaxis with ganciclovir (GCV) did not improve the transplantation outcome because of neutropenia caused by GCV. 1, 2 Therefore, the initiation of GCV triggered by the detection of CMV reactivation is currently the standard strategy for preventing CMV disease. [3] [4] [5] A CMV antigenemia assay has been widely used to monitor CMV reactivation. However, the details of preemptive therapy still need to be clarified, including the threshold number of antigenemia-positive cells for deciding when to start GCV, the dose and duration of GCV and so on. We previously showed that a risk-adapted preemptive therapy, in which the cutoff number of antigenemia-positive cells for deciding when to start GCV was changed according to the risk for CMV disease, was appropriate in allogeneic SCT recipients, but the incidence of neutropenia was still high. 6 Therefore, in the next study, we evaluated the feasibility of preemptive therapy with low-dose GCV, and the findings showed that the initial dose of GCV could be safely decreased to 5 mg/kg. 7 The PCR used to detect CMV DNA has also been investigated for its ability to monitor CMV reactivation. 8 PCR using whole blood samples might be too sensitive as a trigger for deciding when to start preemptive therapy compared with an antigenemia assay or PCR using plasma samples. 9, 10 However, the recent development of real-time PCR has enabled the quantification of CMV DNA. Several studies have shown the feasibility of preemptive therapy guided by real-time PCR monitoring using either whole blood or plasma samples. [11] [12] [13] [14] As for whole blood real-time PCR, Gerna et al. performed two randomized controlled trials of PCR and antigenemia, one in young patients (0-25 years old) and the other in older patients (20-67 years old). 12, 13 They showed that a threshold value of 10 000 copies per ml for determining when to start GCV by whole blood PCR significantly reduced the use of GCV compared with a threshold in which GCV is started at any level of positive antigenemia. However, the study included heterogeneous patients in terms of donor type, stem cell source and GVHD prophylaxis. In particular, antithymocyte globulin was used in approximately half of the patients, and this may have strongly affected the incidence of CMV reactivation and disease. 15, 16 In addition, preemptive therapy guided by antigenemia assay could be more appropriately performed by using a cutoff based on the number of positive cells.
Therefore, we performed a randomized controlled trial of plasma real-time PCR with a cutoff of 300 copies per ml and an antigenemia assay with a cutoff of three positive cells per two slides in a homogenous population of unrelated BMT recipients who received GVHD prophylaxis with a calcineurin inhibitor and MTX.
Patients and methods

Patients
Patients were eligible for the study if they were between 20 and 55 years old, would undergo BMT without in vivo or ex vivo T-cell depletion from an HLA-matched unrelated donor using a myeloablative conditioning regimen and had a good performance status without significant organ dysfunction, as defined in the protocol. Either the donor, the recipient or both must have been seropositive for CMV. Prophylaxis against GVHD was limited to a combination of CYA and MTX, but a combination of tacrolimus and MTX was allowed after June 2002. Patients were enrolled before starting a conditioning regimen, but randomization was performed between day 10 and day 12 after transplantation to exclude patients who developed significant organ dysfunction early after transplantation. This study was approved by the institutional review board of each participating center and a written informed consent was obtained from each patient (UMIN-CTR C000000347).
CMV monitoring methods
Cytomegalovirus antigenemia assay was performed as described previously. 17 In brief, 1.5 Â 10 5 peripheral blood leukocytes were attached to a slide using a cytocentrifuge and fixed with formaldehyde. The cells were sequentially immunostained with MoAb C10/11 (Clonab CMV; Biotest, Dreieich, Germany) and reacted with goat alkaline phosphatase-labeled anti-mouse Ig (Mitsubishi Kagaku Iatron Inc, Tokyo, Japan). Under a light microscopy, CMV-positive cells were counted and the results are presented as the sum of the number of positive cells per two slides.
Real-time PCR was performed using primers and a TaqMan probe for immediate early genes using serum samples. 18 Briefly, DNA extracted from 100 ml of plasma was subjected to PCR using TaqMan Universal PCR Master Mix (PE Biosystems, Foster City, CA, USA) and the PCR product was detected as an increase in the fluorescent intensity using ABI Prism 7700 (PE Biosystems). Real-time fluorescent measurements were taken and a threshold cycle (CT) value for each sample was calculated by determining the point at which the fluorescence exceeded 10 times the baseline fluorescence. A standard curve was constructed using the CT values obtained from serially diluted DNA extracted from a plasmid that contains the respective region of CMV. The CT values from the clinical samples were plotted on the standard curve and the copy number was calculated automatically using Sequence Detection System version 1.6 (PE Biosystems).
Preemptive therapy against CMV disease
Patients were randomly assigned to the antigenemia group or the PCR group using a random block design. Assignment was stratified by the institute, age and the presence or absence of GVHD at the time of randomization. CMV reactivation was monitored weekly by both the antigenemia assay and PCR in all patients, but only the results of the assigned monitoring method were returned to the physicians. Preemptive therapy with GCV was started at an induction dose of 5 mg/kg/day when three or more CMVpositive cells per two slides were detected in the antigenemia group and 300 or more CMV DNA copies per ml were detected in the PCR group. The dose of GCV was increased to 10 mg/kg/day when a rising CMV load was observed. The dose of GCV was decreased to 5 mg/kg/day when a declining CMV load was observed in patients who were receiving GCV at 10 mg/kg/day. A rising and declining CMV load was defined as an increase and decrease in the CMV load by 50% or more of the previous value, respectively. However, changes in antigenemiapositive cells by less than five cells per two slides and changes in the DNA copy number by less than 500 copies per ml were regarded as a stable CMV load. When the CMV load fell below the threshold to start GCV, the dose of GCV was decreased to 5 mg/kg/day, if the patient was receiving GCV at 10 mg/kg/day, and GCV was discontinued if the patient was receiving GCV at 5 mg/kg/day. The dose of GCV was adjusted according to the renal function. 19 CMV monitoring was continued until all of the following three requirements were fulfilled: (i) More than 100 days had passed after transplantation; (ii) More than 2 weeks had passed after the last administration of GCV; and (iii) Absence of the use of (methyl-)prednisolone at 0.5 mg/kg/day or more. 20 
Definition of CMV disease
All patients with symptoms compatible with CMV disease such as interstitial pneumonia, colitis and gastritis underwent extensive pathological and microbiological examination of biopsy specimens. The diagnosis of CMV disease was made by histopathological examination and immunochemical staining of biopsy specimens. However, CMV retinitis was diagnosed when CMV DNA was detected by PCR using aqueous humor samples associated with characteristic retinal changes by ophthalmoscopy. Early and late CMV diseases were defined as those occurring before and after day 100, respectively.
Statistical considerations
The primary end point of the study was the incidence of early CMV disease. We defined success as the absence of CMV disease before day 100. Noninferiority was predefined as a difference in the success rates between the antigenemia group and the PCR group of no more than 10 percentage points. On the basis of the assumption of a success rate of 95% in the PCR group and 90% in the antigenemia group, 39 patients in each treatment group were required to show noninferiority with an alpha error of 5% and a power of 80%, which permitted a 10% difference in the success rate. On the basis of the assumption of a 20% loss of patients between the enrollment and randomization, a total of 96 patients needed to be enrolled in this study. Comparisons for dichotomous and continuous variables between groups were performed with Fisher's exact test and t-test, respectively. Pearson's correlation coefficient was calculated to compare the results of the two monitoring methods after logarithmic transformation.
Results
Incidence of CMV reactivation and the use of GCV A total of 96 patients were enrolled in the study between January 2002 and March 2007. Among these patients, eight patients were excluded because of the use of tacrolimus as GVHD prophylaxis in one, negative CMV Ab in both the donor and recipient in one and organ dysfunction after the conditioning regimen in six. Therefore, a total of 88 patients were randomized into the antigenemia group (n ¼ 45) or the PCR group (n ¼ 43) (Figure 1 ). There were no differences in age, sex, background disease, CMV serostatus, conditioning regimen or GVHD prophylaxis between the two groups ( Table 1 ). In addition, the incidence of grade II-IV acute GVHD was similar (42 vs 47%, P ¼ 0.67).
Cytomegalovirus reactivation, defined as a detection of CMV at any level, was more frequently observed in the antigenemia group (40 of 45 patients, 88.9%) than in the $ Continue monitoring until all of the following requirements are fulfilled. 1) More than 100 days passed after transplantation 2) More than 2 weeks passed after the last administration of ganciclovir 3) Absence of the use of (methyl-)prednisolone at 0.5 mg/kg/day or more. # Decrease the dose of ganciclovir to 5 mg/kg/day if the patient is receiving ganciclovir at 10 mg/kg/day. Stop ganciclovir if the patient is receiving ganciclovir at 5 mg/kg/day. & Rising and declining CMV load were defined as an increase and decrease in the CMV load by 50% or more of the previous value, respectively. However, changes in antigenemia-positive cells by less than 5 cells/ 2 slides and changes in DNA copy number by less than 500 copies/ml were regarded as stable CMV load. Table 2 ). The probability of starting GCV was significantly higher in the antigenemia group than in the PCR group (73.3 vs 44.2%, P ¼ 0.0089, Figure 2) . The results of PCR in the antigenemia group and those of the antigenemia assay in the PCR group were disclosed after the completion of the study. A good correlation was seen between the results of PCR and the antigenemia assay (Po0.0001, r 2 ¼ 0.38, Figure 3 ). Of the 33 patients who received GCV in the antigenemia group, PCR and the antigenemia assay reached the threshold simultaneously in five patients and PCR reached the threshold before starting GCV in only four patients (Figures 4a and 5a ). In the other 24 patients, the CMV DNA copy number was persistently below the threshold until GCV was started. On the other hand, in 11 of 19 patients who received GCV in the PCR group, the results of the antigenemia assay reached the threshold earlier in 11 patients and simultaneously in 7 patients (Figures 4b and 5b) . The results of the antigenemia assay were persistently below the threshold until GCV was started in only one patient. The median number of antigenemia-positive cells at the start of GCV was 5 (range: 3-102) and 47 (range: 0-2921) in the antigenemia and PCR groups, respectively (Figure 6a , P ¼ 0.0051). The median CMV DNA copy number was negative (range: 0-4400) and 750 (range: 310-13000) in the antigenemia and PCR groups, respectively (Figure 6b, Po0.0001) .
Among the 52 patients who received preemptive therapy with GCV at 5 mg/kg/day, only 13 and 7 patients in the antigenemia and PCR groups, respectively, experienced a rising CMV load and required dose-escalation to 10 mg/kg/ day, suggesting that the initiation of GCV at 5 mg/kg was appropriate. 
CMV diseases
Early CMV disease was diagnosed in 1 of the 45 patients (2.2%) in the antigenemia group and 2 of the 43 patients (4.7%) in the PCR group (P ¼ 0.61). These patients exclusively developed CMV colitis. Another patient in the PCR group showed characteristic retinal changes and was presumptively treated with GCV, although CMV infection was not detected in either the aqueous humor or the peripheral blood. The 95% confidence interval for the difference in the success rate was À10.1 to 5.2%, and thus was just outside the predefined lower limit of À10%. However, as shown in Table 3 , the development of CMV disease in the PCR group could not be avoided even if these patients were assigned to the antigenemia group, as either the antigenemia assay and PCR reached the threshold simultaneously (UPN32) or the antigenemia assay did not reach the threshold before the diagnosis of CMV disease (UPN35). All of these patients were successfully treated with GCV or foscarnet, although one patient (UPN35) showed the recurrence of colitis after day 100. None of the other patients developed late CMV disease.
Adverse events during preemptive therapy
The mean duration of preemptive therapy with GCV and the mean total dose of GCV was 23.2±19.4 days and 140.8 ± 129.7 mg/kg in the antigenemia group and 20.8±14.2 days and 118.4±91.2 mg/kg in the PCR group (P ¼ 0.64 and P ¼ 0.51), respectively. Neutropenia with a neutrophil count of o500 per ml was observed in 5 of the 33 patients in the antigenemia group and 3 of the 19 patients in the PCR group (P40.99). Only one patient in the antigenemia group required a discontinuation of GCV because of neutropenia. The total dose of GCV was higher in patients who developed neutropenia, but this difference was not statistically significant (163.8 ± 82.5 vs 126.9 ± 121.4, P ¼ 0.42). An increase in the serum creatinine level by at least 0.5 mg per 100 ml was observed in 8 of the 33 patients in the antigenemia group and in none of the 19 patients in the PCR group (P ¼ 0.039). The total dose of GCV was significantly higher in patients who developed renal impairment (255.0 ± 198.0 vs 106.0 ± 45.5, P ¼ 0.0004).
Discussion
In this randomized controlled trial, we compared plasma real-time PCR with a cutoff at 300 copies per ml and an antigenemia assay with a cutoff at three positive cells per two slides as a trigger for deciding when to start preemptive therapy with GCV after unrelated BMT. GCV was used significantly less frequently in the PCR group. A comparison of the number of antigenemia-positive cells and the CMV DNA copy number at the start of GCV treatment clearly revealed that plasma PCR was significantly less sensitive than the antigenemia assay, at least with the current cutoff values. Although the 95% confidence interval for the difference in the successful prevention rate was just outside the predefined lower limit of À10%, and therefore, we could not show the noninferiority of the PCR group, the incidence of CMV disease was limited to two patients even in the PCR group. In addition, prevention of CMV pneumonia, the main aim of preemptive therapy, was completely achieved in both groups. These findings suggest that an antigenemia assay with a cutoff of three positive cells per two slides was too sensitive and resulted in the unnecessary use of GCV.
The unnecessary use of GCV may be reduced if the cutoff value for the antigenemia assay is increased. The antigenemia assay has already been shown to be not sensitive enough for detecting gastrointestinal involvement by CMV even with a low threshold. 21 In this study, the median number of antigenemia-positive cells at the start of GCV treatment was 47 in the 19 patients who received preemptive therapy in the PCR group. Figure 7 shows the serial changes in the number of antigenemia-positive cells in the patients of the PCR group who developed positive antigenemia that reached the threshold, but who did not receive GCV at that time. In about half of the patients, antigenemia spontaneously became negative without GCV treatment. On the other hand, seven patients developed high-grade antigenemia of over 100 positive cells per two slides. However, GCV was started when the number of positive cells was 260 (median, range: 73-1262 cells) and none of these patients developed CMV disease. Although patients who developed grade II-IV acute GVHD or who received steroid at 0.5 mg/kg or higher experienced highgrade antigenemia more frequently than those who did not develop grade II-IV acute GVHD and did not receive steroid (Figures 7a and b) , the use of GCV was comparable (54.5 vs 40%, P ¼ 0.67). Thus, although it is difficult to determine the appropriate cutoff value for the antigenemia assay, we thought that it may be worth trying to apply a cutoff value of 20 positive cells per two slides, which we are already safely using in allogeneic hematopoietic SCT from an HLA-matched sibling donor, 20 to transplantation from an unrelated donor.
Although Boeckh et al. 3 reported a 14% incidence of early CMV disease using the same cutoff as in the current study, the incidences of positive antigenemia at any level and three or more positive cells per two slides were similar to those in this study (79 and 70% in Boeckh's study and 89 and 73% in the current study). Therefore, the higher incidence of early CMV disease probably resulted from the high incidence (35%) of grade III-IV acute GVHD in their study rather than from the difference in the method used for the antigenemia assay, as acute GVHD is one of the strongest risk factors for CMV disease.
Nevertheless, it is important to note that the sensitivity and specificity of these assays vary depending on the methodology used. 9, [22] [23] [24] In fact, the unexpected differences in the sensitivities of the two assays in this study could be explained by the difference in the methodology used in the antigenemia assay. The cutoffs used for the antigenemia assay and real-time PCR were determined based on our previous study in which HRP-C7 Ab was used in the antigenemia assay. 18 In this study, however, we used C10/ C11 Ab in the antigenemia assay, as this Ab has been used worldwide. Although we did not believe that there are clinical differences between these two antigenemia assays, 6 ,7,20 we should have tested the correlation between the results of plasma PCR and the antigenemia assay using C10/C11 Ab. Fortunately, the unexpected difference in the sensitivity in these assays contributed to the finding that the antigenemia assay with the current cutoff was too sensitive as a trigger for deciding when to start preemptive therapy. These data are valid only when the same methodology is used, and standardization of the methods is warranted. 25, 26 In conclusion, CMV colitis could not be completely prevented by the current preemptive strategy using the peripheral blood samples, but CMV pneumonia was completely prevented in both groups. The initiation of GCV at 5 mg/kg/day was confirmed to be safe, provided the CMV load continues to be monitored. Plasma PCR with a cutoff at 300 copies per ml seemed to be appropriate for monitoring CMV reactivation after transplantation. The cutoff number of positive cells should be raised above that used here when using an antigenemia assay. However, the appropriateness of the threshold of these assays may be different on the basis of the methodology and patient background, such as the risk of GVHD, and therefore, it is difficult to generalize. 
